Joint Clinical Trials Office

You are here

Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a History of Cancer (SAPPHIRE)

Clinical Trial Details

This is a prospective, multi-center, observational study designed to determine if specific agents used for treatment of inflammatory bowel disease (IBD) are associated with the development of new or recurrent cancer in patients with IBD and a history of cancer.

 Commitments for enrollment include:

  • A baseline 15-minute questionnaire related to demographics and health at your clinic visit
  • A yearly 15-minute follow-up questionnaire (one every 12 months for a period of 5 years), either in person, over the phone, or email, to see if there were changes to your health and/or IBD/cancer conditions

Note: No invasive tests (blood tests, x-rays, endoscopies, or other procedures) will be performed for the purpose of this research study. No drugs or devices will be administered to you as part of this study.

    

 

Key Eligibility: 
  • Age 18 or older at entry
  • Diagnosis of Crohn’s disease, ulcerative colitis, or indeterminate colitis
  • Have IBD and a diagnosis of a new or prior cancer diagnosis within the last 5 years

Exclusion Criteria

  • Current enrollment in a clinical trial of an investigational therapy for Crohn’s disease or ulcerative colitis
  • IBD patients with a cancer diagnosis > 5 years prior to study entry
  • IBD patients with active chemotherapy or radiation cancer treatment at enrollment

 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Fatiha Chabouni
(212) 746-5109
fac2005@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1608017458

Status

Open to Enrollment

Age Group

Adult

Sponsor